Navigation Links
FDA Begins Process To Remove Breast Cancer Indication From Avastin Label
Date:12/16/2010

SILVER SPRING, Md., Dec. 16, 2010 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration announced today that the agency is recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The agency is making this recommendation after reviewing the results of four clinical studies of Avastin in women with breast cancer and determining that the data indicate that the drug does not prolong overall survival in breast cancer patients or provide a sufficient benefit in slowing disease progression to outweigh the significant risk to patients. These risks include severe high blood pressure; bleeding and hemorrhage; the development of perforations (or "holes") in the body, including in the nose, stomach, and intestines; and heart attack or heart failure.

In July 2010, after reviewing all available data an independent advisory committee, composed primarily of oncologists, voted 12-1 to remove the breast cancer indication from Avastin's label.  

"After careful review of the clinical data, we are recommending that the breast cancer indication for Avastin be removed based on evidence from four independent studies," Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research. "Subsequent studies failed to confirm the benefit observed in the original trial. None of the studies demonstrated that patients receiving Avastin lived longer and patients receiving Avastin experienced a significant increase in serious side effects. The limited effects of Avastin combined with the significant risks led us to this difficult decision. The results of these studies are disappointing. We encourage the company to conduct additional research to identify if there may be select groups of patients who might benefit from this drug."

Removing the breast cancer indication from the Avastin label will be a process. This is the first step. The drug itself is not being removed from the market and today's action will not have any immediate impact on its use in treating breast cancer. Today's action will not affect the approvals for colon, kidney, brain, and lung cancers.

Oncologists currently treating patients with Avastin for metastatic breast cancer should use their medical judgment when deciding whether a patient should continue treatment with the drug or consider other therapeutic options.

The agency has informed Genentech, Avastin's manufacturer, of its proposal to withdraw marketing approval of the drug for breast cancer. Genentech has not agreed to remove the breast cancer indication voluntarily, so the agency has issued a Notice of Opportunity for a Hearing, which permits Genentech to request a public hearing if it wishes to contest the agency's determination. The company has 15 days to request a hearing; if it does not do so, the hearing will be waived, and FDA will begin proceedings to remove the breast cancer indication.  

Avastin, in combination with chemotherapy (paclitaxel), was approved in February 2008 under the FDA's accelerated approval program, based on the results of a clinical trial known as "E2100," which evaluated the drug in patients who had not received chemotherapy for their metastatic HER2-negative breast cancer. Under the accelerated approval program, a drug may be approved based on clinical data that suggest the drug has a meaningful clinical benefit, with more information being needed to confirm this.  The program provides earlier patient access to promising new drugs to treat serious or life-threatening conditions while confirmatory clinical trials are conducted.

After the accelerated approval of Avastin for breast cancer, Genentech completed additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on "progression-free survival" without evidence of an improvement in overall survival or a clinical benefit to patients sufficient to outweigh the risks. The small increase in "progression-free survival" reflects a small, temporary effect in slowing tumor growth.

Avastin has also been associated with several other serious and potentially life-threatening side effects including the risk of stroke, wound healing complications, organ damage or failure; and the development of a neurological condition called reversible posterior leukoencephalopathy syndrome (RPLS), characterized by high blood pressure, headaches, confusion, seizures, and vision loss from swelling of the brain.

On the basis of all available data relating to the use of Avastin to treat metastatic breast cancer, the agency has determined that the risks of the drug outweigh the benefits for this use.

FDA is open to working with Genentech on any proposals to conduct additional studies of Avastin in patients with metastatic breast cancer designed to identify a population of patients in which the drug's benefits exceed the risks.

For more information:

FDA: Bevacizumab (marketed as Avastin) Information

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm193900.htm

NCI: Breast Cancer

http://www.cancer.gov/cancertopics/types/breast

#

Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
2. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
3. BiondVax Begins Phase IIa Study for Universal Flu Vaccine
4. LIG Assets, Inc. Begins Distribution and Marketing of Unique CPAP Mask Cleaner
5. China PharmaHub Corp. Begins Trading Under Stock Symbol CPHB Instead of WRLC
6. Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
7. Sysmex America Begins Distribution of CellaVision® DM1200
8. Renhuang Begins Trading on NYSE Amex
9. Par Pharmaceutical Begins Shipment of Generic Zegerid®
10. Curemark Begins Autism Trials at Two More Sites
11. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... OXFORD, England , May 24, 2016 ... Practice and Education in Clinical Neurophysiology  ... medical information products and services, today announced the launch ... , an open access journal that focuses on clinical ... latest research, case reports, clinical series, normal values and ...
(Date:5/23/2016)... India , May 23, 2016 ... report "Patient Handling Equipment Market by Product (Wheelchair, ... of Care (Bariatric Care, Critical Care, Wound), Accessories ... - Forecast to 2021", published by MarketsandMarkets, the ... USD 17.18 Billion by 2021 at a CAGR ...
(Date:5/23/2016)... 23, 2016 Transparency Market Research ... Pancreatic Insufficiency Market - Global Industry Analysis, Size, Share, ... to the report, the exocrine pancreatic insufficiency market is ... 2015 to 2023 to reach US$2.85 Bn by 2023. ... characterized by the deficiency of the exocrine pancreatic enzymes, ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... The World Molecular ... through Molecular Imaging.” The focus of ADDMI-IG will be geared towards how using ... pipeline issues. Through ADDMI-IG WMIS will provide a platform for productive discussions about ...
(Date:5/25/2016)... ... May 25, 2016 , ... TransactRx ... real time adjudication of medical service claims by Pharmacy Benefit Managers that were ... claims management software. The TransactRx Cross Benefit Clearinghouse receives standard professional medical claims ...
(Date:5/25/2016)... ... , ... For more than fifty years, we've suffered whiplash as each new scientific study seemed ... the latest nutritional advice – advice that was supposed to keep us healthy and slim. ... American adults are considered to be overweight and more than 1 in 3 adults are ...
(Date:5/25/2016)... ... May 25, 2016 , ... Consumer access to organic foods and ... Kashi®, a maker of whole grain cereals and other plant-based foods, will introduce the ... hard red winter wheat processed by Hesco/Dakota Organic Products. , The transitional designation means ...
(Date:5/24/2016)... ... May 24, 2016 , ... According to an article published ... randomly assigned to reduce the amount of calories they consumed by 25% experienced some ... weight enjoyed better sleep, improved quality of life, and enhanced sexual function compared to ...
Breaking Medicine News(10 mins):